AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01565707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solifenacin Succinate Suspension
Description: Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
Study NCT01565707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate Suspension
Description: Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
Study NCT01565707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
Study NCT01565707 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Urotherapy
Description: Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
Study NCT03600922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the patella was resurfaced.
Description: Patellar resurfacing was undertaken using a cemented, inset domed component in TKA.
Study NCT01565707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urotherapy
Description: Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
Study NCT04209673 — intervention group
Intervention type: OTHER
Intervention: Multimodal Pain management including TENS unit
Description: Patient receiving multimodal pain management strategies which includes the use of TENS.
Study NCT04209673 — intervention group
Intervention type: OTHER
Intervention: Multimodal Pain management not including TENS unit
Description: Patient receiving multimodal pain management strategies which does not includes the use of TENS.
Study NCT00661141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antizol
Study NCT00422786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP-232
Description: Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
Study NCT06584669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil
Description: The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).
Study NCT06584669 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules contain a medium-chain triglyceride (MCT) oil obtained by fractionation of coconut and palm kernel oil, which has no detectable levels of EPA, DHA, astaxanthin, or phospholipids.
Study NCT01792206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar
Description: Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
Study NCT01792206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
Study NCT02240940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parachute Implant
Description: CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
Study NCT02496078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Daclatasvir tablet 60mg
Study NCT00148616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
Study NCT02496078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daclatasvir
Description: Daclatasvir tablet 60mg
Study NCT02496078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asunaprevir
Description: Asunaprevir soft capsule 100 mg
Study NCT00661141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00148616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
Study NCT01562821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
Study NCT02496078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asunaprevir
Description: Asunaprevir soft capsule 100 mg
Study NCT01327170 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Subthreshold diode micropulse laser
Study NCT01327170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subthreshold diode micropulse laser
Study NCT04210063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: IMT is a breathing training technique customized to participant's breathing capacity. Using a handheld electronic manometer (Pro2Fit from Smithfield), a study personnel will initiate training at 40-60% maximal inspiratory pressure. Adjustments will be customized to where the participant reports a difficulty of training between 4-6 out of 10. Training sessions will be performed about 30 minutes a day for 28 consecutive days.
Study NCT04768816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride in control group
Study NCT04768816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Autism Spectrum Disorder for safety and effect evaluation.
Study NCT01562821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
Study NCT01562821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An initial placebo bolus dose followed by placebo every second hour until completion of surgery
Study NCT00866502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sNN0031
Description: Continuous ICV infusion for two weeks
Study NCT01039727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care as usual + 5 specific CDs
Description: care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
Study NCT01039727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care as usual + email assistance + AurelisOnLine (AoL) + CDs
Description: care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
Study NCT03279757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES 5 minutes
Description: Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study NCT03279757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES 15 minutes
Description: Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study NCT03279757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES 25 minutes
Description: Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study NCT03279757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC 5 minutes
Description: Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study NCT00866502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continous ICV infusion
Study NCT01393314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Honeywell HomMed Telemonitor
Description: telemonitoring post hospitalization
Study NCT04593641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: administered
Study NCT03279757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC 15 minutes
Description: Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study NCT03279757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC 25 minutes
Description: Topical application of LTC with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study NCT03279757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study NCT00661141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: oral dose of ethanol (0.5 g/kg)
Study NCT01909934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin IV infusion
Study NCT02814318 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaginal and rectovaginal swab cultures
Description: The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
Study NCT01811550 — intervention group
Intervention type: OTHER
Intervention: Glycemic Control
Study NCT03279757 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
Study NCT03919422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T2 paravertebral block
Description: Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
Study NCT03919422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interscalene brachial plexus block and superficial cervical plexus block
Description: An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
Study NCT03919422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene brachial plexus block and superficial cervical plexus block
Description: An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
Study NCT01233791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Diazepam Suppository
Description: 10mg compounded vaginal suppository
Study NCT01233791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Suppository
Description: Patients will be asked to use one vaginal suppository every night for 28 days
Study NCT03591068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: OPN-375 186 μg BID, Delivered via exhalation delivery system
Study NCT00554515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD IL2
Study NCT02491840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy of Gastric and cardia adenocarcinomas
Study NCT00833638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet orally daily
Study NCT00833638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil
Description: Orally once daily
Study NCT00833638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Orally once daily
Study NCT03371420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-AD
Study NCT03371420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET Scan
Study NCT03371420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draws
Study NCT00307827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visilizumab
Description: Visilizumab administered intravenously once per day for two days
Study NCT01178086 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab IV
Study NCT03977220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel combined with S-1
Description: Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
Study NCT00596440 — intervention group
Intervention type: DRUG
Intervention: Transdermal nicotine patch
Description: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
Study NCT03969719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03969719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: 150 mg once daily
Study NCT03969719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919
Description: 300 mg once daily
Study NCT03838042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Entinostat
Description: Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
Study NCT01166633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Description: pitavastatin 2mg per daily
Study NCT01166633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 10mg per daily
Study NCT02130193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin
Description: Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
Study NCT02130193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive danirixin matching placebo
Study NCT01248338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol succinate
Description: once daily 50 or 100 mg for one year
Study NCT01248338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: once daily 5 mg capsule for one year
Study NCT01142206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
Study NCT01142206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
Study NCT01142206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
Study NCT01142206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
Study NCT01142206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV Watching + Physical Activity
Description: The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
Study NCT01667432 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
Study NCT03276676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FLT
Description: PET exams of \[18F\]FLT will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor > 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
Study NCT03276676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluciclovine
Description: PET exams of \[18F\]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor > 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
Study NCT02246140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral MRI and MRA
Study NCT02246140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral MRI and MRA
Study NCT01864564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Screen
Description: Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
Study NCT02269670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT02269670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO
Study NCT02269670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO
Study NCT02269670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given PO
Study NCT02269670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given IM or PO